BioSpace News Archive

Curemark, LLC announced today that results from its Phase 3 clinical trial, the Blüm Study, were presented at the International Society of Autism Research (INSAR) Annual Meeting held in Montreal, Canada from May 1-4, 2019.

ARTISAN-SNM study results were presented on May 5 at the 2019 American Urological Association (AUA) Annual Meeting in Chicago by Professor Howard Goldman, M.D., of the Cleveland Clinic.

PIN Pharma, a company focused on modulating the immune system and having its first indication in oncology, today announced the Company will be presenting a poster at the 55th Annual meeting of ASCO in Chicago on June 1 between 8:00 AM – 11:00 reporting the results of the first-in-human trial evaluating the immune activation and safety of PIN-2 administered to patients with advanced solid tumors.

SL-279252 is the first Agonist Redirected Checkpoint molecule to enter clinical development from the Shattuck pipeline.

Phase 3 drug candidate targeting molluscum

Welltower Inc. (NYSE: WELL) today announced that Ayesha Menon and Edward Cheung have joined the Company as Senior Vice Presidents of Investments.

Financial and company results for the first quarter of 2019

Patients with relapsing remitting multiple sclerosis (RRMS) who received Sanofi’s Lemtrada® (alemtuzumab) experienced improvements in treatment satisfaction and health-related quality of life, according to investigational data from two clinical studies

These results will be presented this week during the 71st annual meeting of the American Academy of Neurology (AAN) in Philadelphia, PA.

Advances have been completed in the manufacturing process for the clinical trial product that will be used in PharmaCyte’s planned clinical trial in locally advanced, inoperable pancreatic cancer